Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06398405
Status:
RECRUITING
Last Update Posted:
2024-05-03
First Post:
2024-04-29
Brief Title:
A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer
Sponsor:
Shandong Cancer Hospital and Institute
Organization:
Shandong Cancer Hospital and Institute
Study Overview
Official Title:
Efficacy and Safety of Epigallocatechin-3-gallate an Important Polyphenolic That Originates From Tea in Patients With Esophageal Squamous Cancer A Phase II Trial
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators conduct this phase II study to evaluate safety and effectiveness of EGCG in patients with dysphagia Swallowing-related dysphagia and pain scores were recorded using the numerical rating scale NRS daily Barium meal radiography was utilized to measure the luminal size and the length of the lesion area both before and after a week of EGCG treatment The scales are translated into Chinese and guides in Chinese are developed instructing how to use the scales and perform the assessments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None